Send PM
Followers 5
Posts 285
Boards Moderated 0
Alias Born 05/29/2011

FREE
MRSN REPORT

Re: None

Wednesday, 03/14/2018 11:39:53 PM

Wednesday, March 14, 2018 11:39:53 PM

Post# of 44
XMT-1522 Late-breaker at AACR in April...

LB-294 / 16 - Synergy of an anti-HER2 ADC TAK-522 (XMT-1522) in combination with anti-PD1 monoclonal antibody (mAb) in a syngeneic breast cancer model expressing human HER2
http://www.abstractsonline.com/pp8/#!/4562/presentation/10611


Also poster on differentiation of ADC platform...
754 / 21 - Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect
http://www.abstractsonline.com/pp8/#!/4562/presentation/3082

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRSN News